Deroofing: A safe, effective and well‐tolerated procedure in patients with hidradenitis suppurativa
Journal of the European Academy of Dermatology and Venereology · 2024-05 · 38 (5) · 931-936
DOI: 10.1111/jdv.19810 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 26.01.2024. Verfasst von P K Krajewski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Patient Satisfaction. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Hidradenitis suppurativa (HS) is a recurrent, debilitating, chronic disorder of the pilosebaceous unit. Although advances in HS treatment have been made, more than 45% of patients remain dissatisfied with systemic treatment, and more than one‐third are dissatisfied with surgical procedures.
Objectives
A prospective, observational study on the deroofing procedures in HS with special attention paid to patient satisfaction and complications.
Methods
HS lesions were assessed clinically and by the use of ultrasound. Patients reported outcomes, including pain, itch and satisfaction, were measured at 24 h post‐surgery by a numeric rating scale (NRS) ranging from 0 to 10. Additionally, the timeline of objective wound closure reported by patients in (weeks), in addition to the need for any analgesics use, were both evaluated.
Results
The mean closure time of the post‐deroofing wound was assessed as 4.4 ± 1.9 weeks. A statistically longer time was necessary for complete closure in males than in females (4.9 ± 2.2 weeks and 3.9 ± 1.6 weeks, respectively; p = 0.046). The closure time correlated positively yet weakly with the HS tunnel's width ( r = 0.27, p = 0.016) and length ( r = 0.228, p = 0.044). Patients assessed mean pain at 24 h post‐op as mild with 0.7 ± 1.2 points according to NRS, with no differences between sexes. Similarly, itch in the first 24 h was assessed as mild with 1.8 ± 1.1 points, without differences between sexes. No pain, itch or adverse events were reported after 1 week following deroofing. Moreover, no cases of wound infection were reported. An overall patient satisfaction was assessed as 9.9 ± 0.4 points (range 9–10 points).
Conclusion
Deroofing is an easy, effective and safe dermatosurgical procedure that does not require surgical experience or operating theatre. It is associated with no complications and very low post‐op pain and should be part of holistic HS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
- Servicio de Dermatologia, Hospital de Manises, Valencia, Spain.
- European Hidradenitis Suppurativa Foundation (EHSF), Dessau-Roßlau, Germany.
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
ORCID-Profile: P K Krajewski, A Martorell
Zitieren
APA
Krajewski, P. K., Sanz-Motilva, V., Flores Martinez, S., Solera, M., Ochando, G., Jfri, A., & Martorell, A. (2024). Deroofing: A safe, effective and well‐tolerated procedure in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 38(5), 931-936. https://doi.org/10.1111/jdv.19810
Vancouver
Krajewski PK, Sanz-Motilva V, Flores Martinez S, Solera M, Ochando G, Jfri A, et al. Deroofing: A safe, effective and well‐tolerated procedure in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology. 2024;38(5):931-936. doi:10.1111/jdv.19810
BibTeX
@article{Krajewski2024,
author = {Krajewski, P K and Sanz-Motilva, V and Flores Martinez, S and Solera, M and Ochando, G and Jfri, A and Martorell, A},
title = {Deroofing: A safe, effective and well‐tolerated procedure in patients with hidradenitis suppurativa},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
volume = {38},
number = {5},
pages = {931--936},
doi = {10.1111/jdv.19810}
}
EUVIMED